Clinical Trials Logo

Filter by:
NCT ID: NCT02638909 Terminated - Cholangiocarcinoma Clinical Trials

Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies

Start date: December 2015
Phase: Phase 2
Study type: Interventional

The available data indicate that Ceritinib has substantial anti-tumor activity in patients with anaplastic lymphoma kinase (ALK) and ROS1 rearranged non-small cell lung cancer (NSCLC). This trial will investigate the potential of Ceritinib in patients with advanced gastrointestinal malignancies with ALK and ROA1 rearrangement, and for whom there is no available therapeutic option.

NCT ID: NCT02638168 Terminated - Clinical trials for Attention Deficit Disorder With Hyperactivity

Effects of Evening Dose of Immediate Release Methylphenidate on Sleep in Children With ADHD

Start date: January 2016
Phase: Phase 4
Study type: Interventional

Over 10% of children in the United States are diagnosed with ADHD, and nearly half of these children have moderate to severe impairments in sleep, further exacerbating their already impaired academic, emotional and social functioning. In children with ADHD, 34% of prescribed sleep medications are antipsychotics that can cause marked weight gain and metabolic changes; alternate medications have either been found to be ineffective, difficult to tolerate or are largely unstudied in youth. Delayed sleep onset is strongly correlated with active symptoms of ADHD and Oppositional Defiant Disorder (ODD), suggesting that better control of disruptive behaviors could improve sleep patterns and this application will assess if the extension of the therapeutic effects of CNS stimulants into the early evening improves sleep onset.

NCT ID: NCT02638129 Terminated - Obesity Clinical Trials

Naltrexone/Bupropion Cardiovascular Outcomes Study

Start date: January 2016
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate cardiovascular (CV) safety of naltrexone hydrochloride (HCl) and bupropion HCl extended release combination (NB) compared with placebo and rule out excess risk of major adverse cardiovascular events (MACE) when given in combination with standard of care in overweight and obese participants with documented history of CV disease.

NCT ID: NCT02637947 Terminated - Clinical trials for Tachycardia, Ventricular

Comparison of VT Ablation Outcomes Using Remote MAGNETIC Navigation Versus Manual Approach in a Low LVEF Population

MAGNETIC-VT
Start date: January 2016
Phase: N/A
Study type: Interventional

The study purpose is to demonstrate that ventricular tachycardia (VT) ablation using the Niobeā„¢ ES system results in superior outcomes compared to a manual approach in subjects with ischemic scar VT in a low ejection fraction population.

NCT ID: NCT02637713 Terminated - Morbid Obesity Clinical Trials

Management of Reflux After Sleeve Using Stretta

MaRSS
Start date: March 2016
Phase: N/A
Study type: Interventional

Gastroesophageal reflux disease (GERD) is a frequently seen entity after sleeve gastrectomy. Management of GERD after sleeve is difficult given limited treatment modalities. Stretta is an endoscopic FDA approved device that improves symptoms of GERD, there is minimal information about its use on patients after sleeve. This registry will attempt to get information regarding the treatment of reflux using Stretta after sleeve gastrectomy.

NCT ID: NCT02636387 Terminated - Anemia, Sickle Cell Clinical Trials

Desmopressin as a Therapy for Bedwetting in Children With Sickle Cell Disease

Start date: August 26, 2015
Phase:
Study type: Observational

This study assesses if using the medication desmopressin will decrease nightime bedwetting in children with sickle cell disease.

NCT ID: NCT02636283 Terminated - Clinical trials for Peripheral Arterial Disease

Use of Entresto Sacubitril/Valsartan for the Treatment of Peripheral Arterial Disease

Start date: December 31, 2017
Phase: Phase 2
Study type: Interventional

This study proposes the use of Entresto (sacubitril/valsartan) to test the effects on pain free walking duration on patients with peripheral arterial disease, a condition caused by decreased blood flow to the muscles in the legs.

NCT ID: NCT02635100 Terminated - Sleep Apnea Clinical Trials

Multinight CPAP for Sleep Apnea Patients

Start date: May 2015
Phase: N/A
Study type: Interventional

Obstructive sleep apnea (OSA) is a prevalent disorders characterized by intermittent obstructions of the upper airway during sleep. Continuous Positive Airway Pressure (CPAP) has been shown to be the most efficacious treatment for OSA. It consists of a small device that provides positive airway pressure delivered by a mask attached to the patients nose/mouth.

NCT ID: NCT02635074 Terminated - Clinical trials for Recurrent Adult Acute Myeloid Leukemia

Ibrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Start date: November 2016
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of ibrutinib when given together with idarubicin and cytarabine in treating patients with acute myeloid leukemia that has returned after a period of improvement or has not responded to previous treatment. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as idarubicin and cytarabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ibrutinib together with idarubicin and cytarabine may kill more cancer cells.

NCT ID: NCT02635061 Terminated - Clinical trials for Non Small Cell Lung Cancer

Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer

Start date: August 25, 2016
Phase: Phase 1
Study type: Interventional

Determine the safety, tolerability, dose limiting toxicities (DLTs), and maximum tolerated dose (MTD) of ACY 241 in combination with nivolumab.